Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?

Oncology (Williston Park, N.Y.)

Volumn 25, Issue 2, 2011, Pages

  Echarri Gonzalez, Maria José ^a   Green, Robin ^b   Muggia, Franco M ^b  

^a HOSPITAL SEVERO OCHOA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

FEMALE; HUMAN; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASM; OVARY TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 79954427316     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)